Proof of concept controlled phase 2 clinical trial data evaluating anavex®2-73 (blarcamesine) in parkinson's disease dementia presented at ctad 2020 conference

Statistically s ignificant improvements in cdr system cognitive domain of attention assessed by choice reaction time (p = 0.039) and digital vigilance (p = 0.008)

AVXL Ratings Summary

AVXL Quant Ranking